| 1.33 -0.11 (-7.64%) | 07-13 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.96  |
1-year : | 2.24 |
| Resists | First : | 1.68 |
Second : | 1.91 |
| Pivot price | 1.65 |
|||
| Supports | First : | 1.29 |
Second : | 1.08 |
| MAs | MA(5) : | 1.51 |
MA(20) : | 1.64 |
| MA(100) : | 1.58  |
MA(250) : | 1.73 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 3.7 |
D(3) : | 13.5 |
| RSI | RSI(14): 32.6 |
|||
| 52-week | High : | 2.44 | Low : | 1.17 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ BYSI ] has closed below the lower bollinger band by 5.6%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ BYSI ] is to continue within current trading range. It is unclear right now based on current values. 66.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.42 - 1.43 | 1.43 - 1.44 |
| Low: | 1.28 - 1.29 | 1.29 - 1.3 |
| Close: | 1.31 - 1.33 | 1.33 - 1.35 |
BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on developing novel cancer treatments. Its flagship product is Plinabulin, a selective immune-modulating and microtubule-binding agent. Plinabulin has successfully advanced through Phase III clinical trials for two distinct applications: the prevention of chemotherapy-induced neutropenia, and the treatment of advanced non-small cell lung cancer. The company is also exploring Plinabulin's efficacy in combination with various immuno-oncology drugs; specifically, alongside nivolumab (a PD-1 antibody) for NSCLC, and with nivolumab and ipilimumab (a CTLA-4 antibody) for small cell lung cancer (SCLC). Furthermore, it is being investigated in conjunction with PD-1 or PD-L1 antibodies and radiation to address a range of cancers. Beyond its lead asset, BeyondSpring's pipeline includes three preclinical-stage small molecule immune agents and a proprietary drug development platform. The company, founded in 2010, maintains its headquarters in New York, New York.
Mon, 06 Jul 2026
BeyondSpring (BYSI) director receives 100,000 stock options grant - Stock Titan
Mon, 06 Jul 2026
BeyondSpring (BYSI) CEO awarded 100,000 stock options at $1.75 strike price - Stock Titan
Mon, 06 Jul 2026
BeyondSpring (BYSI) CEO Qiu Min reports direct holding of 2,498 Ordinary Shares - Stock Titan
Mon, 06 Jul 2026
BeyondSpring (BYSI) CFO Li Na submits initial Form 3 ownership filing - Stock Titan
Thu, 25 Jun 2026
BeyondSpring Inc. Actuals & Estimates (NASDAQ:BYSI) - TradingView
Mon, 22 Jun 2026
BeyondSpring Inc. (BYSI) Slips 2.48%: Stock Tests Key Support at $1.49 - Cumulative Volume - DonanımHaber
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 41 (M) |
| Shares Float | 32 (M) |
| Held by Insiders | 14.2 (%) |
| Held by Institutions | 14.5 (%) |
| Shares Short | 2,220 (K) |
| Shares Short P.Month | 2,210 (K) |
| EPS | -0.21 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.84 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -19.3 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.21 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -19 (M) |
| Levered Free Cash Flow | 12 (M) |
| PE Ratio | -6.34 |
| PEG Ratio | 0 |
| Price to Book value | -1.59 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.91 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|